NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

Technology Appraisal guidance no.179; Sunitinib for the treatment of gastrointestinal stromal tumours

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
Manufacturers/sponsors	appeal) General
Sunitinib (Pfizer)	 Board of Community Health Councils in Wales
Patient/carer groups	British National Formulary
 Afiya Trust Beating Bowel Cancer Black Health Agency Bowel Cancer Information Bowel Cancer UK Cancer Black Care Cancer Equality Colostomy Association Counsel and Care Equalities National Council GIST Support UK Helen Rollason Heal Cancer Charity IA (Ileostomy and Internal Pouch Support Group) Macmillan Cancer Support Maggie's Centres 	 Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium
 Marie Curie Cancer Care Muslim Council of Britain Muslim Health Network Ochre Oesophageal Patients Association Ostomy Lifestyle Centre Rarer Cancers Foundation Sarcoma UK South Asian Health Foundation Specialised Healthcare Alliance Stomach Cancer Awareness Network 	 Imatinib (Novartis) <u>Relevant research groups</u> Bowel & Cancer Research CORE (Digestive Disorders Foundation) Institute of Cancer Research MRC Clinical Trials Unit National Cancer Research Institute National Cancer Research Network National Institute for Health Research Research Institute for the Care of Older People
 Tenovus <u>Professional groups</u> Association of Cancer Physicians Association of Coloproctologists of Great Britain Association of Surgeons of Great Britain and Ireland Bladder and Bowel Foundation 	 <u>Assessment Group</u> Assessment Group tbc National Institute for Health Research Health Technology Assessment Programme

National Institute for Health and Clinical Excellence Technology Appraisal guidance no.179; Sunitinib for the treatment of gastrointestinal stromal tumours

Consultees	Commentators (no right to submit or appeal)
 British Association for Services to the Elderly British Association of Surgical Oncology British Association of Surgical Oncology British Institute for Radiology British Psychosocial Oncology Society British Society of Gastroenterology Cancer Network Pharmacists Forum Cancer Research UK Pelican Cancer Foundation Royal College of Anaesthetists Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal College of Surgeons Royal College of Surgeons Royal Society of Medicine Society and College of Radiographers United Kingdom Oncology Nursing Society Others Department of Health NHS Bristol Welsh Government 	Associated Guideline Groups • National Collaborating Centre for Cancer Associated Public Health Groups • Tbc

PTO for definition of consultees and commentators

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, the British National Formulary, and the British Medical Association.

Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.